<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10320121</article-id>
    <article-id pub-id-type="pmid">37158247</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkad348</article-id>
    <article-id pub-id-type="publisher-id">gkad348</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Web Server Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ACFIS 2.0: an improved web-server for fragment-based drug discovery via a dynamic screening strategy</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Shi</surname>
          <given-names>Xing-Xing</given-names>
        </name>
        <xref rid="FN1" ref-type="author-notes"/>
        <aff><institution>National Key Laboratory of Green Pesticide, Key Laboratory of Pesticide &amp; Chemical Biology, Ministry of Education, Central China Normal University</institution>, <addr-line>Wuhan</addr-line><addr-line>430079</addr-line>, <country country="TW">P.R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Zhi-Zheng</given-names>
        </name>
        <xref rid="FN1" ref-type="author-notes"/>
        <aff><institution>National Key Laboratory of Green Pesticide, Key Laboratory of Pesticide &amp; Chemical Biology, Ministry of Education, Central China Normal University</institution>, <addr-line>Wuhan</addr-line><addr-line>430079</addr-line>, <country country="TW">P.R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Fan</given-names>
        </name>
        <xref rid="FN1" ref-type="author-notes"/>
        <aff><institution>National Key Laboratory of Green Pesticide, Key Laboratory of Pesticide &amp; Chemical Biology, Ministry of Education, Central China Normal University</institution>, <addr-line>Wuhan</addr-line><addr-line>430079</addr-line>, <country country="TW">P.R. China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4090-8411</contrib-id>
        <name>
          <surname>Hao</surname>
          <given-names>Ge-Fei</given-names>
        </name>
        <!--gefei_hao@foxmail.com-->
        <xref rid="COR2" ref-type="corresp"/>
        <aff><institution>National Key Laboratory of Green Pesticide, Key Laboratory of Pesticide &amp; Chemical Biology, Ministry of Education, Central China Normal University</institution>, <addr-line>Wuhan</addr-line><addr-line>430079</addr-line>, <country country="TW">P.R. China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4384-2593</contrib-id>
        <name>
          <surname>Yang</surname>
          <given-names>Guang-Fu</given-names>
        </name>
        <!--gfyang@mail.ccnu.edu.cn-->
        <xref rid="COR1" ref-type="corresp"/>
        <aff><institution>National Key Laboratory of Green Pesticide, Key Laboratory of Pesticide &amp; Chemical Biology, Ministry of Education, Central China Normal University</institution>, <addr-line>Wuhan</addr-line><addr-line>430079</addr-line>, <country country="TW">P.R. China</country></aff>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 027 67867800; Email: <email>gfyang@mail.ccnu.edu.cn</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Ge-Fei Hao. Tel: +86 027 67867706; Email: <email>gefei_hao@foxmail.com</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first three authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>7</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-05-09">
      <day>09</day>
      <month>5</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>09</day>
      <month>5</month>
      <year>2023</year>
    </pub-date>
    <volume>51</volume>
    <issue>W1</issue>
    <fpage>W25</fpage>
    <lpage>W32</lpage>
    <history>
      <date date-type="accepted">
        <day>23</day>
        <month>4</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>11</day>
        <month>4</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>04</day>
        <month>3</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkad348.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Drug discovery, which plays a vital role in maintaining human health, is a persistent challenge. Fragment-based drug discovery (FBDD) is one of the strategies for the discovery of novel candidate compounds. Computational tools in FBDD could help to identify potential drug leads in a cost-efficient and time-saving manner. The Auto Core Fragment <italic toggle="yes">in silico</italic> Screening (ACFIS) server is a well-established and effective online tool for FBDD. However, the accurate prediction of protein-fragment binding mode and affinity is still a major challenge for FBDD due to weak binding affinity. Here, we present an updated version (ACFIS 2.0), that incorporates a dynamic fragment growing strategy to consider protein flexibility. The major improvements of ACFIS 2.0 include (i) increased accuracy of hit compound identification (from 75.4% to 88.5% using the same test set), (ii) improved rationality of the protein-fragment binding mode, (iii) increased structural diversity due to expanded fragment libraries and (iv) inclusion of more comprehensive functionality for predicting molecular properties. Three successful cases of drug lead discovery using ACFIS 2.0 are described, including drugs leads to treat Parkinson's disease, cancer, and major depressive disorder. These cases demonstrate the utility of this web-based server. ACFIS 2.0 is freely available at <ext-link xlink:href="http://chemyang.ccnu.edu.cn/ccb/server/ACFIS2/" ext-link-type="uri">http://chemyang.ccnu.edu.cn/ccb/server/ACFIS2/</ext-link>.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <caption>
            <p>ACFIS 2.0 is a one-stop platform for fragment-based drug design, aiming to help users obtain novel ligand structures for specific protein targets.</p>
          </caption>
          <graphic xlink:href="gkad348figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32125033</award-id>
        <award-id>21837001</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>Drugs save lives and improve health; thus, the discovery of novel drugs for various diseases is an important scientific issue. However, developing a new approved drug costs $1.5–2.0 billion and requires 10–15 years on average (<xref rid="B1" ref-type="bibr">1</xref>). Therefore, developing effective approaches to improve the success rate and reduce the cost for drug discovery is important (<xref rid="B2" ref-type="bibr">2</xref>). Lead discovery is a critical stage in drug research and development. The goal of this stage is to identify candidate molecules with satisfactory pharmacological activity. Lead discovery is accomplished through multiple iterations of compound design, synthesis, and bioassays. Surprisingly, it is estimated that approximate 100 000 compounds are synthesized at this stage for the development of a new drug (<xref rid="B3" ref-type="bibr">3</xref>). The poor efficiency of drug lead generation fundamentally restricts the progress of drug discovery. Therefore, the exploitation and application of helpful methodologies or tools for accelerating lead generation and optimization are pressing needs.</p>
    <p>Fragment-based drug design (FBDD), a powerful methodology to identify quality leads starting from small sized molecules, has rapidly advanced in recent decades (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>). Due to the weak binding of fragments to proteins, a variety of biophysical technologies, such as nuclear magnetic resonance (NMR) (<xref rid="B6" ref-type="bibr">6</xref>), X-ray diffraction (<xref rid="B7" ref-type="bibr">7</xref>), and surface plasmon resonance (SPR) (<xref rid="B8" ref-type="bibr">8</xref>), are more commonly employed in FBDD. However, fragment screening using these technologies is limited to only hundreds or thousands due to the expense, long experimental time, and high demand for purified raw materials (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>). On the other hand, computational approaches have fewer limitations and large-scale screening (up to million) can be accomplished. In addition, computational approaches allow many molecular properties, such as synthetic accessibility, to be considered in advance. FBDD accelerated by computational tools has been successfully applied in the discovery of six approved drugs and over 40 candidates in clinical trials (<xref rid="B11" ref-type="bibr">11–13</xref>). For example, the discovery and development of vemurafenib took only 6 years from project initiation to approval (<xref rid="B14" ref-type="bibr">14</xref>). Overall, computational approaches exhibit great strengths in screening efficiency and economic cost.</p>
    <p>A number of FBDD-derived computational methods or tools have been developed recently. According to the steps of FBDD they participate in, these computational tools can be divided into two categories: fragment screening tools and fragment optimization tools. Fragment optimization tools to determinate the core fragment include the fragment docking software like SEED (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>) and the molecular decomposition tools like DAIM (<xref rid="B17" ref-type="bibr">17</xref>). Fragment optimization tools to generate lead compound include fragment growing tools like Frag_PELE (<xref rid="B18" ref-type="bibr">18</xref>) and DeepFrag (<xref rid="B19" ref-type="bibr">19</xref>) and fragment linking tools like DeLinker (<xref rid="B20" ref-type="bibr">20</xref>) and Syntalinker (<xref rid="B21" ref-type="bibr">21</xref>). These tools play important roles in expediting the FBDD process. Previously, we developed a comprehensive web server that facilitates FBDD named Auto Core Fragment <italic toggle="yes">in silico</italic> Screening (ACFIS) (<xref rid="B22" ref-type="bibr">22</xref>). A key innovation of ACFIS is the integration of multiple computation models to achieve a more integral workflow from fragment screening to lead generation. ACFIS is a useful tool that facilitates lead compound identification (<xref rid="B23" ref-type="bibr">23–26</xref>). However, protein flexibility was not fully estimated for the prediction of fragment binding and optimization in the previous version.</p>
    <p>Here, we present ACFIS 2.0, an updated version based on a dynamic fragment growing method that considers the influence of protein flexibly. Additionally, ACFIS 2.0 integrates molecular visualization and various molecular property prediction functions into the output interface. Tested on 122 reported cases covering 51 targets (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>), ACFIS 2.0 achieved an accuracy of 88.5%. Compared to the previous version, the accuracy of ACFIS 2.0 is increased by more than 10% (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>). In addition, the prediction results produced by ACFIS 2.0 for potential bioactive compounds are more comprehensive, covering binding affinity, physicochemical properties, drug-likeness, and synthetic accessibility. It results in better identification of high-quality drug hits. To demonstrate the applicability of ACFIS 2.0, the case studies of applying this tool to design monoamine oxidase B (MAO-B), tropomyosin receptor kinase A (TRKA), and serotonin transporter (SERT) inhibitors as Parkinson's drug, anticarcinogen, and antidepressant are presented. The usability and performance of the upgraded ACFIS is significantly improved. ACFIS 2.0 could serve as a powerful platform for FBDD research to accelerate drug discovery.</p>
  </sec>
  <sec id="SEC2">
    <title>PROGRAM DESCRIPTION</title>
    <sec id="SEC2-1">
      <title>Workflow overview</title>
      <p>The overall workflow for FBDD using ACFIS 2.0 can be divided into four steps with two modules (Figure <xref rid="F1" ref-type="fig">1A</xref>). The starting module, named CORE_GEN, is designed to generate a core fragment from a given ligand structure. This module is comprised of two steps: fragment deconstruction and core fragment identification. The purpose of the second module, named CAND_GEN, is to derive candidate compounds from the core fragment. The CAND_GEN module is comprised of two sequential steps: dynamic fragment growing based on the core fragment (identified in the first module) and molecular property evaluation for candidate selection. The core process of the ACFIS 2.0 pipeline is organized based on our previously developed pharmacophore-linked fragment virtual screening (PFVS) method (<xref rid="B27" ref-type="bibr">27</xref>). The details of the four steps are described in <xref rid="sup1" ref-type="supplementary-material">Supplementary Text S1</xref>.</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Overview of the ACFIS 2.0 workflow, input, and output. (<bold>A</bold>) The flow diagram of the CORE_GEN and CAND_GEN modules in ACFIS 2.0. (<bold>B</bold>) The panel for submission of a task on the Home page and a subsequent page for ligand selection. (<bold>C</bold>) The result page of a task in one-stop mode. The contents include a list of newly generated ligands, an interactive viewer of protein-ligand binding modes, and the predicted results of physicochemical properties, binding free energy, drug/pesticide-likeness evaluation and synthesis accessibility.</p>
        </caption>
        <graphic xlink:href="gkad348fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC2-2">
      <title>Server usage</title>
      <sec id="SEC2-2-1">
        <title>Input</title>
        <p>The input requirements of the one-stop mode on the ‘Home’ page are relatively simple (Figure <xref rid="F1" ref-type="fig">1B</xref>). First, a protein-ligand complex structure is required by uploading a PDB file or typing the 4-letter PDB code. The uploaded complex structure could be experimentally-determined, or derived from computational models (e.g. using molecular docking approach). In some cases where experimental protein 3D structures are not available, it is feasible to obtain docked complex structures using predicted protein structures by AlphaFold (<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>). Then, one of five fragment libraries is allowed to be specified for fragment growing. A fragment library derived from approved drugs is the default option. Optional inputs include an email address for notification about the job state, job name, and password to privatize the job. Once these initial inputs are submitted, a ‘Select Ligand’ page will appear. On this page, all ligands in the given complex structure are shown and the user is asked to choose a structure for virtual screening.</p>
        <p>Inputs for the two advanced modes are slightly different from the one-stop mode. In CORE_GEN mode, only one protein-ligand complex structure is indispensable, and other inputs are optional, similar to in the one-stop mode. The ‘Select Ligand’ page appears after the initial submission in CORE_GEN. In CAND_GEN mode, the input requirements for the initial page and the ‘Select Ligand’ page are the same as the one-stop mode, but a protein-fragment complex structure is recommended. The subsequent page requires another input; all hydrogen atoms of the specified ligand are automatically labeled with numbers, and the user selects a hydrogen atom as the fragment growing point by entering its corresponding number.</p>
      </sec>
      <sec id="SEC2-2-2">
        <title>Output</title>
        <p>The outputs of ACFIS 2.0 include a list of compounds, a 3D visual presentation of protein-ligand binding, and three tables of molecular properties (Figure <xref rid="F1" ref-type="fig">1C</xref>). For tasks in one-stop mode, the results derived from CAND_GEN and CORE_GEN are separately displayed using two subpages. On the left side of the output (sub)page, a navigation list of all newly generated compounds is shown. The listed compounds can be potential drug hits derived from CAND_GEN or core fragments derived from CORE_GEN, and each compound is equipped with ‘VIEW’ and ‘DOWNLOAD’ buttons. On the right side of the output page, a presentation of prediction results for each compound, which varies with the click of a ‘VIEW’ button, is shown. The binding mode of the ligand with its surrounding protein residues is visualized via the 3D interactive viewer on the upper right of the page. The property prediction data, including physicochemical properties, binding free energy, drug/pesticide-likeness evaluation, is summarized in tables at the bottom right of the output page. All of compound structures and result tables can be downloaded.</p>
      </sec>
    </sec>
  </sec>
  <sec id="SEC3">
    <title>NEW FEATURES AND UPDATES</title>
    <sec id="SEC3-1">
      <title>Expanded fragment libraries for increased structural diversity</title>
      <p>In ACFIS 2.0, the original two libraries have been updated and two new libraries have been added to expand the structural diversity of generated ligands (Figure <xref rid="F2" ref-type="fig">2A</xref>). The first version of ACFIS contained only the FDA Drug Fragment Library and the Pesticide Fragment Library for fragment growing. In the current version, four fragment libraries are embedded, including the Approved Drug Fragment Library, the Approved Pesticide Fragment Library (<xref rid="B30" ref-type="bibr">30</xref>), the Hotspot Binding Fragment Library (<xref rid="B31" ref-type="bibr">31</xref>) and the Kinase Inhibitor Fragment Library (<xref rid="B32" ref-type="bibr">32</xref>).</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>New features and updates of ACFIS 2.0, including (<bold>A</bold>) expanded fragment libraries, (<bold>B</bold>) a dynamic fragment strategy, (<bold>C</bold>) improved interactive design (C), and (D) drug likeness evaluation.</p>
        </caption>
        <graphic xlink:href="gkad348fig2" position="float"/>
      </fig>
      <p>The main updates of deployed fragments in ACFIS 2.0 include: (i) the removal of highly similar fragments from the original two libraries based on a Tanimoto coefficient of 0.7, (ii) a supplementation with a series of novel fragments extracted from recently approved drugs and pesticides, (iii) the addition of 96 fragments that bind to the most preferred hotspots of popular drug targets (experimentally confirmed), (iv) the addition of 255 fragments that occur at a high frequency in kinase inhibitors and (v) the integration of the aforementioned four theme-specific fragment libraries.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Rational dynamic strategy for fragment growing</title>
      <p>A new feature of ACFIS 2.0 is the dynamic fragment growing strategy that allows broad sampling of core fragment-bound protein conformations (Figure <xref rid="F2" ref-type="fig">2B</xref>). In the first version of ACFIS, only one receptor protein-core fragment complex conformation was used as a template to link fragments from the fragment library to the core fragment when constructing new compounds. This single protein-fragment complex conformation was originally deconstructed directly from the inputted protein-ligand complex structure without multiple sampling. This treatment ignored protein flexibility, probably resulting in a high probability of losing fragment-bound protein conformations at local energy minima and, thus, an unreasonable starting point for fragment growing. In ACFIS 2.0, molecular dynamics (MD) simulation of the protein-core fragment complex structure and conformation clustering of the MD trajectory are added before fragment growing (<xref rid="B33" ref-type="bibr">33</xref>), enabling an ensemble of complex structures at significantly different energy states (<xref rid="sup1" ref-type="supplementary-material">Supplementary Text S1</xref>). Therefore, the subsequent fragment growing is performed based on more than one protein-core fragment complex conformations, resulting in the generation of more protein-ligand conformations. This refinement of the fragment growing strategy rationalizes the previously proposed PFVS and may improve ACFIS 2.0 performance.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Improved function of design and analysis</title>
      <sec id="SEC3-3-1">
        <title>Interactive webpage design</title>
        <p>The interface of ACFIS 2.0 was redesigned to make job submission and the prediction result display more intuitive (Figure <xref rid="F2" ref-type="fig">2C</xref>). First, a function was added to show 2D molecular graphs for all ligands in the uploaded complex structure, allowing users to select a ligand of interest for a FBDD task. Second, when inputting CAND_GEN jobs, a 3D molecular graph of the core fragment labeled with hydrogen atom numbers was provided to aid users in specifying link points. Third, new compound navigation was implemented on the output page, allowing users to browse the prediction results of different compounds on the same page through mouse click. Furthermore, a web-based interactive viewer was implemented to provide 3D visualization of ligand-bound protein macromolecules, powered by NGL (<xref rid="B34" ref-type="bibr">34</xref>). In the viewer, users can interactively manipulate the complex structures, showing binding modes from different perspectives.</p>
      </sec>
      <sec id="SEC3-3-2">
        <title>Physicochemical property analysis</title>
        <p>New physicochemical property prediction functions for the generated compounds were added to ACFIS 2.0, providing basic structural information about the ligand/core fragment. The predicted physicochemical properties include SIMLES, molecular weight, number of heavy atoms, number of hydrogen bond donors, number of hydrogen bond acceptors, polar surface area, logP, number of rings, number of aromatic rings, number of rotated bonds and number of aromatic bonds.</p>
      </sec>
      <sec id="SEC3-3-3">
        <title>Drug/pesticide-likeness evaluation</title>
        <p>Another feature of ACFIS 2.0 is the inclusion of drug/pesticide-likeness evaluation to complement the original binding affinity evaluation (Figure <xref rid="F2" ref-type="fig">2D</xref>). This feature supports the identification of computationally generated compounds that are more likely to be drug/pesticide leads for subsequent synthesis. Three drug-likeness rules or scoring functions are used, including Lipinski's drug-likeness rule (<xref rid="B35" ref-type="bibr">35</xref>), the drug-likeness rule of Ghose <italic toggle="yes">et al.</italic> (<xref rid="B36" ref-type="bibr">36</xref>), and a quantitative estimate of drug-likeness (QED) scoring (<xref rid="B37" ref-type="bibr">37</xref>). The pesticide-likeness rule proposed by Hao <italic toggle="yes">et al.</italic> is employed (<xref rid="B38" ref-type="bibr">38</xref>). In addition, a synthetic accessibility score based on molecular complexity and fragment contributions is also provided on the output page.</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC4">
    <title>RESULTS</title>
    <sec id="SEC4-1">
      <title>Performance and comparison</title>
      <p>The performance of ACFIS 2.0 in generating active ligands from core fragments was assessed by ranking predicted binding affinities. The detailed validation protocol was provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Text S2 and Figure S2</xref>. A test dataset of 122 cases covering 51 protein targets and a specific fragment library was used (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1 and Figure S3</xref>). These cases were carefully collected from the literature. Sixty-one tested compounds that exhibited high experimental binding affinities or <italic toggle="yes">in vitro</italic> activities were considered positive samples; the remaining 61 compounds showed relatively low affinities or activities were considered negative samples. The input protein-core fragment complex structures were obtained by deconstructing the protein-ligand complexes reported in the PDBbind database (<xref rid="B39" ref-type="bibr">39</xref>). The CAND_GEN mode was used for testing. The output rank of the tested compound among all generated ligands was the criterion for estimating whether this prediction is true. As shown in Figure <xref rid="F3" ref-type="fig">3A</xref>, ACFIS 2.0 achieved an accuracy of 88.5%, a precision of 87.3%, a specificity of 86.8%, and a sensitivity value of 90.1%. Compared to previous version (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>), the accuracy of ACFIS 2.0 is increased by &gt;10%. Thus, ACFIS 2.0 performed well in discovering fragment-derived compounds with potentially high bioactivity.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Performance and key feature of ACFIS 2.0. (<bold>A</bold>) The predictive performance of ACFIS 2.0 validated on a test set of 122 cases. (<bold>B</bold>) Comparison of key features of ACFIS 2.0 with other computational tools for fragment-based drug discovery (FBDD). Compared to most of other tools, ACFIS 2.0 is one of the few tools that covers the global workflow of FBDD.</p>
        </caption>
        <graphic xlink:href="gkad348fig3" position="float"/>
      </fig>
      <p>A comprehensive comparison of ACFIS 2.0 with other computational tools designed for FBDD was performed (Figure <xref rid="F3" ref-type="fig">3B</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). Most of tools only focus on a specific step of the FBDD workflow. SEED (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>) aims to improve the fragment docking accuracy to obtain potent core fragments, while DAIM (<xref rid="B17" ref-type="bibr">17</xref>) and eMolFrag (<xref rid="B40" ref-type="bibr">40</xref>) were designed for structural fragmentation to extract core fragment from bioactive compounds. Tools for fragment-to-lead optimization are often organized according to the drug design strategies. For example, Frag_PELE (<xref rid="B18" ref-type="bibr">18</xref>) and DeepFrag (<xref rid="B19" ref-type="bibr">19</xref>) are used to perform fragment growing with a predetermined core fragment. DeLinker (<xref rid="B20" ref-type="bibr">20</xref>), SyntaLinker (<xref rid="B21" ref-type="bibr">21</xref>) and Ligbuilder (<xref rid="B41" ref-type="bibr">41</xref>) can link two or more different core fragments into a new lead compound. On the whole, ACFIS 2.0 is one of the few web-based tools to apply a one-stop workflow for FBDD, featuring pipeline presentation covering fragment library construction, core fragment identification and fragment-to-lead optimization.</p>
    </sec>
    <sec id="SEC4-2">
      <title>Case study 1: optimization of a highly potent MAO-B inhibitor for treating parkinson's disease</title>
      <p>Inhibition of MAO-B is an effective treatment for Parkinson's disease (PD) (<xref rid="B42" ref-type="bibr">42</xref>). The MAO-B inhibitor, safinamide, is the only one approved Parkinson's drug. To discover more potent MAO-B inhibitors, Jin <italic toggle="yes">et al.</italic> used ACFIS 2.0 for structural optimization starting from safinamide structure (Figure <xref rid="F4" ref-type="fig">4A</xref>) (<xref rid="B43" ref-type="bibr">43</xref>). First, the crystal structure of the MAO-B and safinamide complex (PDB ID: 2v5z) was inputted into the CORE_GEN mode to obtain a list of computational core fragments. Fragment <bold>1</bold>, which had the highest ligand efficiency (LE) among all output fragments, it was selected as the core fragment to start the CAND_GEN job. The complex structure of MAO-B with fragment <bold>1</bold> was uploaded and the Comprehensive Fragment Library was specified for fragment growing. Then, ACFIS 2.0 provided a series of fragment <bold>1</bold>-derived compounds as potential new MAO-B ligands. Among them, compound <bold>C3</bold> exhibited a lower calculated binding free energy than safinamide, which was inferred to be bioactive toward MAO-B. Eventually, compound <bold>C3</bold> was synthesized and assayed. The experimentally-derived MAO-B inhibitory activity of compound <bold>C3</bold> (IC<sub>50</sub> = 21nM) was 10-fold higher than the inhibitory activity of safinamide (IC<sub>50</sub> = 249 nM), demonstrating the dependability of ACFIS 2.0.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>Three cases of fragment-based drug discovery applications using ACFIS 2.0. (<bold>A</bold>) Design of a monoamine oxidas-B inhibitor for treating Parkinson's disease based on safinamide. (<bold>B</bold>) Design of a tropomyosin receptor kinase inhibitor for cancer therapies based on larotrectinib. (<bold>C</bold>) Design of a serotonin transporter inhibitor for treating depression based on vilazodone.</p>
        </caption>
        <graphic xlink:href="gkad348fig4" position="float"/>
      </fig>
    </sec>
    <sec id="SEC4-3">
      <title>Case study 2: design of a less drug-resistant TRK inhibitor for cancer therapies</title>
      <p>Tropomyosin receptor kinases (TRKs) are an important class of anti-tumor targets (<xref rid="B44" ref-type="bibr">44</xref>). Larotrectinib was the first approved TRK drug (<xref rid="B45" ref-type="bibr">45</xref>), but patients develop resistance problem induced by protein mutations, such as TRKA<sup>G595R</sup> (<xref rid="B46" ref-type="bibr">46</xref>). To seek for less drug-resistant TRK inhibitors, Wang <italic toggle="yes">et al.</italic> performed FBDD using ACFIS 2.0 (Figure <xref rid="F4" ref-type="fig">4B</xref>) (<xref rid="B32" ref-type="bibr">32</xref>). First, the structure of the TRKA<sup>G595R</sup> mutant protein was constructed by computationally mutating key residues on the holo-TRK crystal structure (PDB ID: 4aoj). The complex structure of Larotrectinib and TRKA<sup>G595R</sup>, which built through molecular docking, was submitted for a CORE_GEN job. Fragment <bold>2</bold> computationally exhibited high binding affinity and the highest LE value. Thus, fragment <bold>2</bold> was used as the core fragment. CAND_GEN was then employed to generate compounds based on fragment <bold>2</bold> and the Comprehensive Fragment Library. Dozens of compounds were generated, and the <bold>YT3</bold> structure had the highest binding affinity score. Experimental results demonstrated that <bold>YT3</bold> inhibited both wild-type TRKA (IC<sub>50</sub> = 4.4 nM) and TRKA<sup>G595R</sup> (IC<sub>50</sub> = 1.02 nM).</p>
    </sec>
    <sec id="SEC4-4">
      <title>Case study 3: discovery of a novel SERT inhibitor with improved drug bioavailability for treating depression</title>
      <p>The serotonin transporter (SERT) is an important pharmacological target for treating major depressive disorder (<xref rid="B47" ref-type="bibr">47</xref>). The SERT inhibitor, vilazodone, is a commercially available anti-depressant drug with insufficient oral bioavailability (<italic toggle="yes">F</italic> = 47.45%). To design novel anti-depressants with improved bioavailability, Wang <italic toggle="yes">et al.</italic> performed SERT-based drug design with the aid of ACFIS 2.0 (Figure <xref rid="F4" ref-type="fig">4C</xref>) (<xref rid="B48" ref-type="bibr">48</xref>). The crystal structure of the vilazodone-SERT complex (PDB ID: 7lwd) was uploaded to launch a CORE_GEN operation. Fragment <bold>3</bold> had an acceptable binding free energy and drug-likeness score for fragment optimization. To optimize the interaction between the core fragment and SERT, the adipose chain of fragment <bold>3</bold> was shortened to obtain fragment <bold>4</bold> as the final core fragment. Fragment growing was performed for fragment <bold>4</bold> using CAND_GEN, and the newly generated compound <bold>DH4</bold> with a high binding affinity was identified for subsequent structural modification. Compound <bold>DH4</bold> exhibits similar binding affinity and significantly improved oral bioavailability (<italic toggle="yes">F</italic> = 83.28%) compared with vilazodone, proving the successful performance of ACFIS 2.0 in this design.</p>
    </sec>
  </sec>
  <sec id="SEC5">
    <title>LIMITATIONS</title>
    <p>Despite the enhanced features of ACFIS 2.0, several limitations need to be considered. For instance, the current ACFIS version relies on protein-ligand complex structures to implement core fragment or compound generation. Thus, ACFIS 2.0 cannot be used fail to work when the protein structure of interest is unknown or not available. In addition, the performance of a job may be negatively affected if the starting complex structures have low accurate binding modes. Further, the workflow of ACFIS 2.0 relies on the assumption that adding a new fragment did not affect the binding mode of the core fragment, but sometimes the opposite is true.</p>
  </sec>
  <sec sec-type="conclusions" id="SEC6">
    <title>CONCLUSION AND OUTLOOK</title>
    <p>In summary, ACFIS 2.0 is an upgraded web server that provides a computational pipeline to implement FBDD. While based on the core functionality of ligand generation from the original version, ACFIS 2.0 was optimized by incorporating improved dynamic fragment growing functionality. In addition, the expanded fragment libraries, comprehensive molecular properties analysis, and user-friendly visualization enable users to investigate generated compounds as potential hits, facilitating more comprehensive drug/pesticide molecular exploration. ACFIS 2.0 was 88.5% accurate in generating expected compounds with appropriate binding affinity rankings when tested on 122 cases. Three typical cases of ACFIS 2.0 applications, improving the designs of MAO-B, SERT and TRK inhibitors, demonstrated the applicability of the server. The new upgrades make ACFIS 2.0 more powerful and user-friendly for FBDD. In the future, further improvements to ACFIS 2.0 will be made, including the addition of a protein-fragment binding scoring function to improve fragment screening performance and the addition of a fragment linking strategy to generate more diverse compounds. ACFIS 2.0 benefited from users’ feedback and our upgrade efforts provide better service.</p>
  </sec>
  <sec sec-type="data-availability" id="SEC7">
    <title>DATA AVAILABILITY</title>
    <p>ACFIS 2.0 is freely available at <ext-link xlink:href="http://chemyang.ccnu.edu.cn/ccb/server/ACFIS2/" ext-link-type="uri">http://chemyang.ccnu.edu.cn/ccb/server/ACFIS2/</ext-link>. The datasets used for the performance validation are provided in the Supplementary data.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkad348_Supplemental_File</label>
      <media xlink:href="gkad348_supplemental_file.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec id="SEC8">
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkad348#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC9">
    <title>FUNDING</title>
    <p>National Natural Science Foundation of China [32125033, 21837001]. Funding for open access charge: National Natural Science Foundation of China.</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harrer</surname><given-names>S.</given-names></string-name>, <string-name><surname>Shah</surname><given-names>P.</given-names></string-name>, <string-name><surname>Antony</surname><given-names>B.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>J.</given-names></string-name></person-group><article-title>Artificial intelligence for clinical trial design</article-title>. <source>Trends Pharmacol. Sci.</source><year>2019</year>; <volume>40</volume>:<fpage>577</fpage>–<lpage>591</lpage>.<pub-id pub-id-type="pmid">31326235</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berdigaliyev</surname><given-names>N.</given-names></string-name>, <string-name><surname>Aljofan</surname><given-names>M.</given-names></string-name></person-group><article-title>An overview of drug discovery and development</article-title>. <source>Future Med. Chem.</source><year>2020</year>; <volume>12</volume>:<fpage>939</fpage>–<lpage>947</lpage>.<pub-id pub-id-type="pmid">32270704</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hughes</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Rees</surname><given-names>S.</given-names></string-name>, <string-name><surname>Kalindjian</surname><given-names>S.B.</given-names></string-name>, <string-name><surname>Philpott</surname><given-names>K.L.</given-names></string-name></person-group><article-title>Principles of early drug discovery</article-title>. <source>Br. J. Pharmacol.</source><year>2011</year>; <volume>162</volume>:<fpage>1239</fpage>–<lpage>1249</lpage>.<pub-id pub-id-type="pmid">21091654</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erlanson</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>B.J.</given-names></string-name>, <string-name><surname>Jahnke</surname><given-names>W.</given-names></string-name></person-group><article-title>Fragment-based drug discovery: advancing fragments in the absence of crystal structures</article-title>. <source>Cell Chem. Biol.</source><year>2019</year>; <volume>26</volume>:<fpage>9</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">30482678</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Murray</surname><given-names>C.W.</given-names></string-name>, <string-name><surname>Rees</surname><given-names>D.C.</given-names></string-name></person-group><article-title>The rise of fragment-based drug discovery</article-title>. <source>Nat. Chem.</source><year>2009</year>; <volume>1</volume>:<fpage>187</fpage>–<lpage>192</lpage>.<pub-id pub-id-type="pmid">21378847</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harner</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Frank</surname><given-names>A.O.</given-names></string-name>, <string-name><surname>Fesik</surname><given-names>S.W.</given-names></string-name></person-group><article-title>Fragment-based drug discovery using NMR spectroscopy</article-title>. <source>J. Biomol. NMR</source>. <year>2013</year>; <volume>56</volume>:<fpage>65</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">23686385</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y.S.</given-names></string-name>, <string-name><surname>Strickland</surname><given-names>C.</given-names></string-name>, <string-name><surname>Voigt</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Kennedy</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Beyer</surname><given-names>B.M.</given-names></string-name>, <string-name><surname>Senior</surname><given-names>M.M.</given-names></string-name>, <string-name><surname>Smith</surname><given-names>E.M.</given-names></string-name>, <string-name><surname>Nechuta</surname><given-names>T.L.</given-names></string-name>, <string-name><surname>Madison</surname><given-names>V.S.</given-names></string-name>, <string-name><surname>Czarniecki</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors</article-title>. <source>J. Med. Chem.</source><year>2010</year>; <volume>53</volume>:<fpage>942</fpage>–<lpage>950</lpage>.<pub-id pub-id-type="pmid">20043700</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Navratilova</surname><given-names>I.</given-names></string-name>, <string-name><surname>Hopkins</surname><given-names>A.L.</given-names></string-name></person-group><article-title>Fragment screening by surface plasmon resonance</article-title>. <source>ACS Med. Chem. Lett.</source><year>2010</year>; <volume>1</volume>:<fpage>44</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">24900174</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Voet</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>K.Y.</given-names></string-name></person-group><article-title>Fragment based drug design: from experimental to computational approaches</article-title>. <source>Curr. Med. Chem.</source><year>2012</year>; <volume>19</volume>:<fpage>5128</fpage>–<lpage>5147</lpage>.<pub-id pub-id-type="pmid">22934764</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Souza Neto</surname><given-names>L.R.</given-names></string-name>, <string-name><surname>Moreira-Filho</surname><given-names>J.T.</given-names></string-name>, <string-name><surname>Neves</surname><given-names>B.J.</given-names></string-name>, <string-name><surname>Maidana</surname><given-names>R.</given-names></string-name>, <string-name><surname>Guimarães</surname><given-names>A.C.R.</given-names></string-name>, <string-name><surname>Furnham</surname><given-names>N.</given-names></string-name>, <string-name><surname>Andrade</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Silva</surname><given-names>F.P.</given-names><suffix>Jr</suffix></string-name></person-group><article-title>In silico strategies to support fragment-to-lead optimization in drug discovery</article-title>. <source>Front. Chem.</source><year>2020</year>; <volume>8</volume>:<fpage>93</fpage>.<pub-id pub-id-type="pmid">32133344</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Esch</surname><given-names>I.J.P.</given-names></string-name>, <string-name><surname>Erlanson</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Jahnke</surname><given-names>W.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>C.N.</given-names></string-name>, <string-name><surname>Walsh</surname><given-names>L.</given-names></string-name></person-group><article-title>Fragment-to-lead medicinal chemistry publications in 2020</article-title>. <source>J. Med. Chem.</source><year>2022</year>; <volume>65</volume>:<fpage>84</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">34928151</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Walsh</surname><given-names>L.</given-names></string-name>, <string-name><surname>Erlanson</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>de Esch</surname><given-names>I.J.P.</given-names></string-name>, <string-name><surname>Jahnke</surname><given-names>W.</given-names></string-name>, <string-name><surname>Woodhead</surname><given-names>A.</given-names></string-name>, <string-name><surname>Wren</surname><given-names>E.</given-names></string-name></person-group><article-title>Fragment-to-lead medicinal chemistry publications in 2021</article-title>. <source>J. Med. Chem.</source><year>2023</year>; <volume>66</volume>:<fpage>1137</fpage>–<lpage>1156</lpage>.<pub-id pub-id-type="pmid">36622056</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Z.Z.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>X.X.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Hao</surname><given-names>G.F.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>G.F.</given-names></string-name></person-group><article-title>Fragment-based drug discovery supports drugging ‘undruggable’ protein-protein interactions</article-title>. <source>Trends Biochem. Sci.</source><year>2023</year>; <pub-id pub-id-type="doi">10.1016/j.tibs.2023.01.008</pub-id>.</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bollag</surname><given-names>G.</given-names></string-name>, <string-name><surname>Tsai</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Ibrahim</surname><given-names>P.</given-names></string-name>, <string-name><surname>Nolop</surname><given-names>K.</given-names></string-name>, <string-name><surname>Hirth</surname><given-names>P.</given-names></string-name></person-group><article-title>Vemurafenib: the first drug approved for BRAF-mutant cancer</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2012</year>; <volume>11</volume>:<fpage>873</fpage>–<lpage>886</lpage>.<pub-id pub-id-type="pmid">23060265</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marchand</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Caflisch</surname><given-names>A.</given-names></string-name></person-group><article-title>In silico fragment-based drug design with SEED</article-title>. <source>Eur. J. Med. Chem.</source><year>2018</year>; <volume>156</volume>:<fpage>907</fpage>–<lpage>917</lpage>.<pub-id pub-id-type="pmid">30064119</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Majeux</surname><given-names>N.</given-names></string-name>, <string-name><surname>Scarsi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Apostolakis</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ehrhardt</surname><given-names>C.</given-names></string-name>, <string-name><surname>Caflisch</surname><given-names>A.</given-names></string-name></person-group><article-title>Exhaustive docking of molecular fragments with electrostatic solvation</article-title>. <source>Proteins</source>. <year>1999</year>; <volume>37</volume>:<fpage>88</fpage>–<lpage>105</lpage>.<pub-id pub-id-type="pmid">10451553</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kolb</surname><given-names>P.</given-names></string-name>, <string-name><surname>Caflisch</surname><given-names>A.</given-names></string-name></person-group><article-title>Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking</article-title>. <source>J. Med. Chem.</source><year>2006</year>; <volume>49</volume>:<fpage>7384</fpage>–<lpage>7392</lpage>.<pub-id pub-id-type="pmid">17149868</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perez</surname><given-names>C.</given-names></string-name>, <string-name><surname>Soler</surname><given-names>D.</given-names></string-name>, <string-name><surname>Soliva</surname><given-names>R.</given-names></string-name>, <string-name><surname>Guallar</surname><given-names>V.</given-names></string-name></person-group><article-title>FragPELE: dynamic Ligand Growing within a Binding Site. A Novel Tool for Hit-To-Lead Drug Design</article-title>. <source>J. Chem. Inf. Model.</source><year>2020</year>; <volume>60</volume>:<fpage>1728</fpage>–<lpage>1736</lpage>.<pub-id pub-id-type="pmid">32027130</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Green</surname><given-names>H.</given-names></string-name>, <string-name><surname>Koes</surname><given-names>D.R.</given-names></string-name>, <string-name><surname>Durrant</surname><given-names>J.D.</given-names></string-name></person-group><article-title>DeepFrag: a deep convolutional neural network for fragment-based lead optimization</article-title>. <source>Chem. Sci.</source><year>2021</year>; <volume>12</volume>:<fpage>8036</fpage>–<lpage>8047</lpage>.<pub-id pub-id-type="pmid">34194693</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Imrie</surname><given-names>F.</given-names></string-name>, <string-name><surname>Bradley</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>van der Schaar</surname><given-names>M.</given-names></string-name>, <string-name><surname>Deane</surname><given-names>C.M.</given-names></string-name></person-group><article-title>Deep generative models for 3D linker design</article-title>. <source>J. Chem. Inf. Model.</source><year>2020</year>; <volume>60</volume>:<fpage>1983</fpage>–<lpage>1995</lpage>.<pub-id pub-id-type="pmid">32195587</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>S.</given-names></string-name>, <string-name><surname>Su</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>C.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H.</given-names></string-name></person-group><article-title>SyntaLinker: automatic fragment linking with deep conditional transformer neural networks</article-title>. <source>Chem. Sci.</source><year>2020</year>; <volume>11</volume>:<fpage>8312</fpage>–<lpage>8322</lpage>.<pub-id pub-id-type="pmid">34123096</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hao</surname><given-names>G.F.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>Y.N.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>F.X.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>X.L.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>F.B.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>G.F.</given-names></string-name></person-group><article-title>ACFIS: a web server for fragment-based drug discovery</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>W550</fpage>–<lpage>W556</lpage>.<pub-id pub-id-type="pmid">27150808</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname><given-names>Y.C.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>W.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>W.C.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Qu</surname><given-names>R.Y.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>H.Y.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>G.F.</given-names></string-name></person-group><article-title>Pharmacophore-oriented discovery of novel 1,2,3-benzotriazine-4-one derivatives as potent 4-hydroxyphenylpyruvate dioxygenase inhibitors</article-title>. <source>J. Agric. Food Chem.</source><year>2022</year>; <volume>70</volume>:<fpage>6644</fpage>–<lpage>6657</lpage>.<pub-id pub-id-type="pmid">35618678</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>W.J.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Hewage</surname><given-names>K.A.H.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>Y.X.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M.X.</given-names></string-name>, <string-name><surname>He</surname><given-names>B.</given-names></string-name>, <string-name><surname>Pei</surname><given-names>R.J.</given-names></string-name>, <string-name><surname>Song</surname><given-names>K.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J.H.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Real-time fluorescence imaging of the abscisic acid receptor allows nondestructive visualization of plant stress</article-title>. <source>ACS Appl. Mater. Interfaces</source>. <year>2022</year>; <volume>14</volume>:<fpage>28489</fpage>–<lpage>28500</lpage>.<pub-id pub-id-type="pmid">35642545</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>B.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name></person-group><article-title>Exploring disordered loops in DprE1 provides a functional site to combat drug-resistance in Mycobacterium strains</article-title>. <source>Eur. J. Med. Chem.</source><year>2022</year>; <volume>227</volume>:<fpage>113932</fpage>.<pub-id pub-id-type="pmid">34700267</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>E.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J.Z.H.</given-names></string-name>, <string-name><surname>Hou</surname><given-names>T.</given-names></string-name></person-group><article-title>End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design</article-title>. <source>Chem. Rev.</source><year>2019</year>; <volume>119</volume>:<fpage>9478</fpage>–<lpage>9508</lpage>.<pub-id pub-id-type="pmid">31244000</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hao</surname><given-names>G.F.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>X.L.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>W.C.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>L.S.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Berry</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>G.F.</given-names></string-name></person-group><article-title>Computational discovery of picomolar Q(o) site inhibitors of cytochrome bc1 complex</article-title>. <source>J. Am. Chem. Soc.</source><year>2012</year>; <volume>134</volume>:<fpage>11168</fpage>–<lpage>11176</lpage>.<pub-id pub-id-type="pmid">22690928</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jumper</surname><given-names>J.</given-names></string-name>, <string-name><surname>Evans</surname><given-names>R.</given-names></string-name>, <string-name><surname>Pritzel</surname><given-names>A.</given-names></string-name>, <string-name><surname>Green</surname><given-names>T.</given-names></string-name>, <string-name><surname>Figurnov</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ronneberger</surname><given-names>O.</given-names></string-name>, <string-name><surname>Tunyasuvunakool</surname><given-names>K.</given-names></string-name>, <string-name><surname>Bates</surname><given-names>R.</given-names></string-name>, <string-name><surname>Žídek</surname><given-names>A.</given-names></string-name>, <string-name><surname>Potapenko</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Highly accurate protein structure prediction with AlphaFold</article-title>. <source>Nature</source>. <year>2021</year>; <volume>596</volume>:<fpage>583</fpage>–<lpage>589</lpage>.<pub-id pub-id-type="pmid">34265844</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varadi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Anyango</surname><given-names>S.</given-names></string-name>, <string-name><surname>Deshpande</surname><given-names>M.</given-names></string-name>, <string-name><surname>Nair</surname><given-names>S.</given-names></string-name>, <string-name><surname>Natassia</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yordanova</surname><given-names>G.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>D.</given-names></string-name>, <string-name><surname>Stroe</surname><given-names>O.</given-names></string-name>, <string-name><surname>Wood</surname><given-names>G.</given-names></string-name>, <string-name><surname>Laydon</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D439</fpage>–<lpage>D444</lpage>.<pub-id pub-id-type="pmid">34791371</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.Z.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>X.L.</given-names></string-name>, <string-name><surname>Hao</surname><given-names>G.F.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>G.F.</given-names></string-name></person-group><article-title>PADFrag: a database built for the exploration of bioactive fragment space for drug discovery</article-title>. <source>J. Chem. Inf. Model.</source><year>2018</year>; <volume>58</volume>:<fpage>1725</fpage>–<lpage>1730</lpage>.<pub-id pub-id-type="pmid">30134653</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bajusz</surname><given-names>D.</given-names></string-name>, <string-name><surname>Wade</surname><given-names>W.S.</given-names></string-name>, <string-name><surname>Satała</surname><given-names>G.</given-names></string-name>, <string-name><surname>Bojarski</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Ilaš</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ebner</surname><given-names>J.</given-names></string-name>, <string-name><surname>Grebien</surname><given-names>F.</given-names></string-name>, <string-name><surname>Papp</surname><given-names>H.</given-names></string-name>, <string-name><surname>Jakab</surname><given-names>F.</given-names></string-name>, <string-name><surname>Douangamath</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Exploring protein hotspots by optimized fragment pharmacophores</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>3201</fpage>.<pub-id pub-id-type="pmid">34045440</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Z.Z.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M.S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>X.X.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Hao</surname><given-names>G.F.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>G.F.</given-names></string-name></person-group><article-title>Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations</article-title>. <source>Brief. Bioinf.</source><year>2022</year>; <volume>23</volume>:<fpage>bbac203</fpage>.</mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shi</surname><given-names>X.X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.Z.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.L.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Hao</surname><given-names>G.F.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>G.F.</given-names></string-name></person-group><article-title>PTMdyna: exploring the influence of post-translation modifications on protein conformational dynamics</article-title>. <source>Brief. Bioinf.</source><year>2022</year>; <volume>23</volume>:<fpage>bbab424</fpage>.</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rose</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Bradley</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>Valasatava</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Duarte</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Prlic</surname><given-names>A.</given-names></string-name>, <string-name><surname>Rose</surname><given-names>P.W.</given-names></string-name></person-group><article-title>NGL viewer: web-based molecular graphics for large complexes</article-title>. <source>Bioinformatics</source>. <year>2018</year>; <volume>34</volume>:<fpage>3755</fpage>–<lpage>3758</lpage>.<pub-id pub-id-type="pmid">29850778</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lipinski</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Lombardo</surname><given-names>F.</given-names></string-name>, <string-name><surname>Dominy</surname><given-names>B.W.</given-names></string-name>, <string-name><surname>Feeney</surname><given-names>P.J.</given-names></string-name></person-group><article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title>. <source>Adv. Drug. Deliv. Rev.</source><year>2001</year>; <volume>46</volume>:<fpage>3</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">11259830</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghose</surname><given-names>A.K.</given-names></string-name>, <string-name><surname>Viswanadhan</surname><given-names>V.N.</given-names></string-name>, <string-name><surname>Wendoloski</surname><given-names>J.J.</given-names></string-name></person-group><article-title>A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases</article-title>. <source>J. Comb. Chem.</source><year>1999</year>; <volume>1</volume>:<fpage>55</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">10746014</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bickerton</surname><given-names>G.R.</given-names></string-name>, <string-name><surname>Paolini</surname><given-names>G.V.</given-names></string-name>, <string-name><surname>Besnard</surname><given-names>J.</given-names></string-name>, <string-name><surname>Muresan</surname><given-names>S.</given-names></string-name>, <string-name><surname>Hopkins</surname><given-names>A.L.</given-names></string-name></person-group><article-title>Quantifying the chemical beauty of drugs</article-title>. <source>Nat. Chem.</source><year>2012</year>; <volume>4</volume>:<fpage>90</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">22270643</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hao</surname><given-names>G.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>G.</given-names></string-name></person-group><article-title>A comparative study on the constitutive properties of marketed pesticides</article-title>. <source>Mol. Inf.</source><year>2011</year>; <volume>30</volume>:<fpage>614</fpage>–<lpage>622</lpage>.</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>R.</given-names></string-name>, <string-name><surname>Fang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S.</given-names></string-name></person-group><article-title>The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures</article-title>. <source>J. Med. Chem.</source><year>2004</year>; <volume>47</volume>:<fpage>2977</fpage>–<lpage>2980</lpage>.<pub-id pub-id-type="pmid">15163179</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Naderi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Alvin</surname><given-names>C.</given-names></string-name>, <string-name><surname>Mukhopadhyay</surname><given-names>S.</given-names></string-name>, <string-name><surname>Brylinski</surname><given-names>M.</given-names></string-name></person-group><article-title>Break down in order to build up: decomposing small molecules for fragment-based drug design with eMolFrag</article-title>. <source>J. Chem. Inf. Model.</source><year>2017</year>; <volume>57</volume>:<fpage>627</fpage>–<lpage>631</lpage>.<pub-id pub-id-type="pmid">28346786</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yuan</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Pei</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lai</surname><given-names>L.</given-names></string-name></person-group><article-title>LigBuilder 2: a practical de novo drug design approach</article-title>. <source>J. Chem. Inf. Model.</source><year>2011</year>; <volume>51</volume>:<fpage>1083</fpage>–<lpage>1091</lpage>.<pub-id pub-id-type="pmid">21513346</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tan</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>Jenner</surname><given-names>P.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S.D.</given-names></string-name></person-group><article-title>Monoamine oxidase-B inhibitors for the treatment of Parkinson's disease: past, present, and future</article-title>. <source>J. Parkinsons Dis.</source><year>2022</year>; <volume>12</volume>:<fpage>477</fpage>–<lpage>493</lpage>.<pub-id pub-id-type="pmid">34957948</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jin</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.Z.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>K.Z.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>T.F.</given-names></string-name>, <string-name><surname>Hao</surname><given-names>G.F.</given-names></string-name></person-group><article-title>Computational fragment-based design facilitates discovery of potent and selective monoamine oxidase-B (MAO-B) inhibitor</article-title>. <source>J. Med. Chem.</source><year>2020</year>; <volume>63</volume>:<fpage>15021</fpage>–<lpage>15036</lpage>.<pub-id pub-id-type="pmid">33210537</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cocco</surname><given-names>E.</given-names></string-name>, <string-name><surname>Scaltriti</surname><given-names>M.</given-names></string-name>, <string-name><surname>Drilon</surname><given-names>A.</given-names></string-name></person-group><article-title>NTRK fusion-positive cancers and TRK inhibitor therapy</article-title>. <source>Nat. Rev. Clin. Oncol.</source><year>2018</year>; <volume>15</volume>:<fpage>731</fpage>–<lpage>747</lpage>.<pub-id pub-id-type="pmid">30333516</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname><given-names>L.J.</given-names></string-name></person-group><article-title>Larotrectinib: first global approval</article-title>. <source>Drugs</source>. <year>2019</year>; <volume>79</volume>:<fpage>201</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">30635837</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fuse</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Okada</surname><given-names>K.</given-names></string-name>, <string-name><surname>Oh-Hara</surname><given-names>T.</given-names></string-name>, <string-name><surname>Ogura</surname><given-names>H.</given-names></string-name>, <string-name><surname>Fujita</surname><given-names>N.</given-names></string-name>, <string-name><surname>Katayama</surname><given-names>R.</given-names></string-name></person-group><article-title>Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers</article-title>. <source>Mol. Cancer Ther.</source><year>2017</year>; <volume>16</volume>:<fpage>2130</fpage>–<lpage>2143</lpage>.<pub-id pub-id-type="pmid">28751539</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cowen</surname><given-names>P.J.</given-names></string-name></person-group><article-title>Serotonin and depression: pathophysiological mechanism or marketing myth?</article-title>. <source>Trends Pharmacol. Sci.</source><year>2008</year>; <volume>29</volume>:<fpage>433</fpage>–<lpage>436</lpage>.<pub-id pub-id-type="pmid">18585794</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Z.Z.</given-names></string-name>, <string-name><surname>Yi</surname><given-names>C.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>T.F.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>K.Z.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.S.</given-names></string-name>, <string-name><surname>Xue</surname><given-names>Y.P.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>J.L.</given-names></string-name>, <string-name><surname>Nie</surname><given-names>B.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Deciphering nonbioavailable substructures improves the bioavailability of antidepressants by serotonin transporter</article-title>. <source>J. Med. Chem.</source><year>2023</year>; <volume>66</volume>:<fpage>371</fpage>–<lpage>383</lpage>.<pub-id pub-id-type="pmid">36598095</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
